Glaxosmithkline yesterday reported a 5% increase in fourth-quarter earnings but forecast that earnings growth would dip this year, despite the introduction of several products, as competition from generic drugs intensifies.
- Text size
Glaxo faces up to tough competition
Glaxosmithkline yesterday reported a 5% increase in fourth-quarter earnings but forecast that earnings growth would dip this year, despite the introduction of several products, as competition from generic drugs intensifies.
